



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/521,928	01/21/2005	Ajay S Bhatnagar	ON/4 - 32602A	6202
1095 7550 04/20/2009				
NOVARTIS				
CORPORATE INTELLECTUAL PROPERTY				
ONE HEALTH PLAZA 104/3				
EAST HANOVER, NJ 07936-1080				
EXAMINER				
JAVANMARD, SAHAR				
ART UNIT		PAPER NUMBER		
1617				
MAIL DATE		DELIVERY MODE		
04/20/2009		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/521,928

Applicant(s)

BHATNAGAR ET AL.

Examiner

SAHAR JAVANMARD

Art Unit

1617

Period for Reply -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 05 March 2009.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 18, 19, 23 and 24 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 18, 19, and 23-24 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SI/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Status of the Application

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 03/05/2009 has been entered.

Claim(s) 18, 19, and 23-24 are pending. Claim(s) 18, 19, and 24 have been amended. Claim(s) 18, 19, and 23-24 are examined herein.

Response to Arguments

Applicant's amendments, with respect to the 112 1st rejection of claims 1 and 10, as it applies to the removal of the term "prevention", have been considered and is hereby withdrawn.

Applicant's arguments with respect to claims 1, 18, 19, and 22-24 rejected under the 103(a) obviousness rejection as being unpatentable over Freyer et al. (European Journal of Internal Medicine, 2000) in view of Reid (N. Engl. J. Med., 2002) and Iqbal (Expert Opin. Pharmacother.), have been fully considered but found not persuasive.

In response to applicant's argument that there is no suggestion to combine the references, the examiner recognizes that obviousness can only be established by

combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988) and *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992). In view of Applicant's amendments, the 103(a) obviousness rejection of the last Office Action has been maintained for reasons of record and modified below as a result of Applicant's claim amendments.

Furthermore, Applicant is arguing specific doses of zoledronic acid and letrozole which are effective in treating bone loss. These arguments are not commensurate in scope of the invention.

Applicant's amendments with respect to claim 10 rejected under the 103(a) obviousness rejection as being unpatentable over Freyer et al. (European Journal of Internal Medicine, 2000) in view of Remington's: The Science and Practice of Pharmacy, Nineteenth Edition, Vol I, 1985, page 806), have been fully considered and the rejection is hereby withdrawn.

In view of Applicant's amendments, the 103(a) obviousness rejection of the last Office Action has been maintained for reasons of record and modified below as a result of Applicant's claim amendments.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 18, 19, and 23-24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Freyer et al. in view of Reid (N. Engl. J. Med., 2002) and Iqbal (Expert Opin. Pharmacother.).

Freyer discloses a study whereby patients with bone marrow involvement (BMI), common in metastatic breast cancer, and pancytopenia are administered a combination regimen including hormone therapy (i.e., anti-estrogens, LH-RH agonists, aromatase inhibitors (anastrozole), and progestin derivatives), repeated low dose

chemotherapy, and bisphosphonates (pamidronate) (page 329-330, Introduction; page 331, see Treatment Strategy).

Freyer further teaches that among the five patients treated, three of them were post-menopausal with bone metastasis having ER+ and/or PR+ receptors (page 330, table 1).

Freyer does not teach specifically teach zoledronic acid as the bisphosphonate or letrozole as the aromatase inhibitor. Additionally, Freyer does not teach that the bisphosphonate is administered once every six months.

Reid teaches administering in zoledronic acid to postmenopausal women with low bone density (page 654, methods). Reid further teaches that zoledronic acid is the most potent bisphosphonate that has been studied in clinical trials to date. Reid further teaches that zoledronic acid is superior to pamidronate in the treatment of cancer-related hypercalcemia. Additionally, Reid teaches that because of its high potency, only small doses are required for the inhibition of bone resorption, and long dosing intervals may be used (page 654, lines 1-6), including administering zoledronic acid at base line and again at six months (page 654, see Treatment).

Iqbal teaches that aromatase inhibitors have been found effective in treating breast cancer in postmenopausal women (page 977, lines 11-13). Iqbal further teaches among other aromatase inhibitors, anastrozole and letrozole are markedly effective in inhibiting *in situ* aromatase activity (page 976, see 2.1.1.1 Endocrine effects; page 977 Table 1).

Additionally, Iqbal teaches that anastrozole and letrozole have both been approved by the FDA as first-line agents for the treatment of advanced breast cancer.

Thus, it would have been obvious to one of ordinary skill in the art at the time of the invention to have employed the administration of an aromatase inhibitor and a bisphosphonate as taught by Freyer, using specifically zoledronic acid as the bisphosphonate and letrozole as the aromatase inhibitor. The motivation to use zoledronic acid as the bisphosphonate to treat bone loss is provided by Reid. As noted above, Reid teaches zoledronic acid as one of the most potent bisphosphonates that has been studied in clinical trials to date. Further, Reid teaches that because of its high potency, only small doses are required for the inhibition of bone resorption, and long dosing intervals may be used. Thus one of ordinary skill in the art is inclined to use a bisphosphonate that exhibits the highest efficacy and least number of administrations required. The motivation to use letrozole as the aromatase inhibitor is provided by Iqbal. As discussed above, Iqbal teaches letrozole as one of the first-line agents for the treatment of advanced breast cancer. It is generally common practice among one of ordinary skill in the art to select the one of the most active analogs in a family of drugs to achieve the most promising results.

Conclusion

Claims 18, 19, and 23-24 are not allowed.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAHAR JAVANMARD whose telephone number is (571) 270-3280. The examiner can normally be reached on 8 AM-5 PM MON-FRI (EST).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

/S. J./

/SREENI PADMANABHAN/

Supervisory Patent Examiner, Art Unit 1617